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Abstract 
 
Background: Migraine is a chronic disabling neurovascular condition that may in part be 
caused by endothelial and cerebrovascular disruption induced by hyperhomocysteinemia. 
We have previous provided evidence that homocysteine lowering by vitamin 
supplementation can reduce migraine disability in females. The current study examined the 
genotypic effects of MTHFR and MTRR gene variants on migraine disability in response to 
vitamin supplementation. 
Method: This was a 6-month randomised, double blinded placebo controlled trial of daily 
B vitamin supplementation (B6, 9 and 12) on homocysteine lowering and reduction of 
migraine disability in 206 female patients diagnosed with migraine with aura.  
Results: Vitamin supplementation significantly reduced homocysteine levels (P<0.001), 
migraine head pain severity (P=0.017) and high migraine disability (P=0.022) in 
migraineurs compared to the placebo effect (P>0.1). When the vitamin treated group was 
stratified by genotype, the C allele carriers of the MTHFR C677T variant showed the a 
higher reduction in homocysteine levels (P<0.001), migraine pain severity (P=0.01) and 
percentage of high migraine disability (P=0.009) compared to TT genotypes. Similarly the 
A allele carriers of the MTRR A66G variants showed a higher level of reduction in 
homocysteine levels (P<0.001), migraine pain severity (P=0.002) and percentage of high 
migraine disability (P=0.006) compared to GG genotypes. Genotypic analysis for both 
genes combined indicated that the treatment effect modification of the MTRR vartiant was 
independent of the MTHFR variant. 
Conclusion: This provided further evidence that vitamin supplementation is effective at 
reducing migraine disability and also that both MTHFR and MTRR gene variants are acting 
independently to influence treatment response in female migraineurs. 
 
Introduction 
Migraine affects about 303 million people in the world according to the World Health 
Organisation  (WHO)  and  is  estimated  to  affect  about  12%  of  the  Caucasian 
population [1, 2]. Homocysteine related dysfunction of the vascular endothelium may 
potentially influence migraine susceptibility [3-5]. Hyperhomocysteinemia related 
endothelial injury may activate trigeminal fibres leading to an inflammatory reaction 
occurring in the meninges, along with dilation of the large cerebral vessels. It is this 
reaction that is thought to participate in the characteristic head pain common in patients 
suffering from migraine with aura (MA)[2, 4, 6]. Various factors determine the levels of 
circulating plasma homocysteine, in particular dietary deficiencies in the co-factors such as 
folic acid, vitamin B12 and B6 essential for metabolising homocysteine and mutations in 
the genes of key enzymes participating in homocysteine metabolism such as cystathionine 
b-synthase (CBS), methylenetetrahydrofolate reductase (MTHFR), methionine synthase 
(MTR) and methionine synthase reductase (MTRR)[7].  
 
The human MTHFR gene mapped to chromosome 1p36.3, catalyses the nicotinamide 
adenine dinucleotide phosphate (NADPH) dependent conversion of 5, 10-
methylenetetrahydrofolate (CH2-THF) to 5-methyltetrahydrofolate (CH3-THF), the 
principal circulatory form of folate and a cofactor for methylation of homocysteine to 
methionine [8, 9]. The C667T polymorphism in the MTHFR gene results in an amino acid 
change at position 222, substituting alanine (Ala) for valine (Val). The TT genotype of the 
C677T polymorphism is associated with 50% reduction in enzyme activity and can lead to 
mild hyperhomocysteinemia [6, 10-12].  This effect is exacerbated in combination with low 
folate levels [13]. Since the first discovery of the MTHFRC677T polymorphism association 
with migraine in a Japanese population, several studies have replicated the findings in 
different independent populations [6, 11, 12, 14]. A meta analysis of 2961 migraine patients 
has provided further evidence that the TT genotype, specifically increases the risk of MA 
[15].  
 
The MTRR gene reduces inactive cobalamin II to active cobalamin I and methylates it to 
methylcobalamin using S-adenosylmethionine as the methyl donor [16]. MTRR therefore 
plays a pertinent role in maintaining adequate supply of active cobalamin I and may also be 
a critical determinant of homocysteine concentrations [17]. A common variant, A66G in the 
MTRR gene results in the replacement of methionine with isoleucine in the enzyme. The 
MTRR A66G polymorphism is also associated with an increase in plasma homocysteine, 
with the GG genotype having a greater effect than AG genotype [17]. In addition the 
coexistence of the MTHFR 677TT genotype and either the AG or GG genotypes for the 
MTRR A66G polymorphism have been reported to magnify the effect of the MTHFR 
677TT genotype alone [18]. 
 
A recent study by Lea et al examined whether folic acid (vitamin B9) and vitamin B6 and in 
fifty two MA sufferers [2]. The major findings of this study revealed that vitamin 
supplementation significantly reduced plasma homocysteine levels and migraine disability, 
in a small subgroup of migraineurs [2]. The results of this trial were supported by the open-
labelled study by Di Rosa et al [10] and provided initial evidence that homocysteine 
lowering through folic acid coupled vitamins B6 and B12 may reduce migraine disability in a 
subgroup of patients[2, 10].  
 
Our initial study provided some evidence that the effect of vitamin supplementation on 
homocysteine-lowering and reduction of migraine disability was influenced by 
MTHFRC677T genotype, whereby C allele carriers were shown to exhibit a greater 
response compated to TT genotypes [2]. With multiple genes reported to be involved in the 
homocysteine-metabolising pathway, it is plausible that different genotypes may cause 
varying response to vitamin supplementation. The current study repeated the original trial 
in an independent and larger sample of migraineurs which allowed us to investigate the 
genotypic effects of both the MTHFR and the MTRR gene on homocysteine lowering and 
migraine disability in response to vitamin supplementation. 
 
Methods 
Study design and participant group 
This study analysed the genotypic effect of the MTHFRC677T and MTRRA66G 
polymorphisms on daily folic acid and B6 and B12 vitamin treatment for lowering 
homocysteine, migraine disability, frequency and pain severity by conducting a 
randomized, double blinded placebo controlled clinical trial over a 6 month period. The 
trial guidelines were designed using the guidelines for controlled trials of drugs in migraine 
[19]. The study recruited female Caucasian adult between the ages of 18 and 60, of 
European ancestry from all over Australia. All participants were interviewed and completed 
a detailed questionnaire that was administered through Griffith University’s Genomics 
Research Centre (GRC). As migraine is more prevalent in females and the possibility that 
there may be a difference in migraine susceptibility and response in relation to treatment, 
the current study only focussed on one gender. Females between the ages of 18 and 60 were 
recruited and participants were included if they had suffered migraine for more than 5 years 
and had a current diagnosis of MA (>90% of their migraine attacks were associated with 
aura), and a 1-year history of severe, long lasting attacks (at least 4 attacks lasting more 
than 48h), had a family history of migraine. Confirmation of migraine diagnosis was carried 
out using the IHS criteria.  Participants who were currently taking vitamin supplementation, 
pregnant, or had been diagnosed with a clinically recognised co-morbid disease such as 
vascular disease, depression or epilepsy were excluded from the trial to reduce clinical and 
pathological heterogeneity. Participants that had taken part in another clinical trial or had 
received any experimental therapy within the last one month were also excluded from the 
trial. The patient group was not selected on the basis of pre existing folic acid, B12 or B6 
deficiency. 
 
Treatment 
245 female patients meeting the inclusion criteria were randomly assigned into either the 
placebo or the treatment group. A blocked random allocation sequence was generated using 
Microsoft Excel (Microsoft, USA). Participants and everyone involved in this trial were 
blinded to randomisation and group allocation. Participants received either Blackmores 
MigraVit 
TM
 vitamin tablets containing 2mg of folic acid, 25mg of vitamin B6 and 400 µg of 
vitamin B12 or the placebo tablet. Participants were instructed to take one tablet daily for 6 
months. Both the vitamin and placebo tablets were produced by Blackmores and were 
identical in appearance.  
 
Baseline and Follow-up assessment 
Before commencing the trial all participants were assessed for migraine disability using the 
Migraine Disability Assessment Score (MIDAS) instrument, which provides a measure of 
productive days lost to migraine headache in previous 3 months ( i.e. migraine disability), 
headache frequency and pain severity [2, 20]. Studies have shown that the MIDAS 
instrument is a valid and clinically useful instrument for assessing health-related quality of 
life in migraineurs. Based on the 5-question MIDAS rating, participants were arbitrarily 
categorized into a ‘low’ disability group if they had a MIDAS rating of 0-10 and into a 
‘high’ disability group if they had a MIDAS rating greater than 11[2, 20, 21] . Questions 6 
and 7 of the MIDAS instrument were on migraine frequency and head pain severity 
respectively. These were measured as number of days with headache (over a 3 month 
period) and a pain score (based on a scale of 1-10), respectively [2, 20, 21]. 
 
Participants were asked to complete a daily diary during the trial period to record the details 
of their migraine symptoms (duration, frequency and severity) and treatment compliance. 
Participants were also instructed to take their usual migraine treatment for acute attacks. A 
blood sample was collected for baseline measurement of plasma homocysteine (µmol/l), 
folate (nmol/l), vitamin B6 and B12 (pmol/l) concentration. 2ml of venous blood was 
collected for Genomic DNA extraction and genotyping purposes.  Participants were 
contacted after 3 months of starting the trial for headache diary and compliance checking. 
At the end of the 6 months trial the patients were reassessed at the GRC clinic. They were 
questioned about their migraine history in the last 6 months since the start of the trial. A 
second collection of blood samples was done for measurement of homocysteine, folate, B6 
and B12 concentrations. The Plasma homocysteine, folate, B6 and B12 levels were measured 
in an accredited pathology laboratory. 
 
 Dietary consumption 
Variation in the participant’s dietary intake of folate is a potential confounding factor for 
this study. Participants were thus required to keep a daily diary of food type, amount and 
frequency. Each participant was given 2 diary packs, each pack consisting of 7 days of 
daily diet intake to be recorded. The diet dairy was designed to estimate the usual dietary 
intake of nutrients such as B6, B12 and dietary folate over a typical week. Participants were 
asked to complete their diet dairy once a fortnight, on only one day until each day of the 
week has been recorded. The nutrient intake of participants was analysed using the 
NUTTAB version 2010 database, which is based on the Australian New Zealand food 
standard code. 
Genotyping 
The C677T polymorphism was genotyped in the patient group in the GRC laboratory using 
previously published methods[6]. High resolution melt analysis was used to genotype 
A66G polymorphisms. Primers used for genotyping the MTRR A66G polymorphism are 
“Forward 5’: GCA AAG GCC ATC GCA GAA GAC AT 3’ and “Reverse 5’: AAA CGG 
TAA AAT CCA CTG TAA CGG C 3’. The reaction mixture used HotStarTaq (Qiagen, 
Hilden Germany) and consisted of 40 ng of genomic DNA, 10× PCR buffer, 25 mM 
MgCl2, 5uM of each primer, 2.5mM of dNTPs, 50 μM of SYTO 9 (Invitrogen, Carlsbad, 
USA), 0.5 U of HotStarTaq polymerase and Polymerase Chain Reaction (PCR) grade water 
in a volume of 25 μL. All PCR reactions were performed in duplicate. PCR cycling and 
HRM analysis was performed on the Rotor-Gene™ 6000 (Corbett Research, Mortlake, 
New South Wales, Australia). The PCR cycling conditions for the MTRR A66G were as 
follows; one cycle of 95°C for 5 minutes; 45 cycles of 95°C for 5 seconds, 45 cycles of 
60°C for 10 seconds, 72°C for 20 seconds; one cycle of 95°C for 1 second, 72°C for 90 
seconds and a HRM step from 75 to 85°C rising at 0.1°C per second. 
 
Statistical analysis 
The analysis for the current trial was conducted on a modified intention-to-treat (ITT) 
principle. The modified ITT population was composed of all randomised participants who 
started the trial and consumed study supplements on at least one occasion, excluding those 
who withdrew from the trial after the randomisation process had taken place but before the 
commencement of study supplement consumption.  
 
At baseline, the unpaired samples t-tests were used to test the group means. The median 
were compared using the Mann Whitney U tests and proportions were compared using the 
χ2 test of independence. The primary hypothesis of this trial, that vitamin supplementation 
reduced migraine disability was tested by comparing proportions of high disability 
migraineurs before and after the 6 month trial in both the vitamin and placebo groups. The 
χ2 test of independence was used to compare the proportion changes. Mean changes were 
compared before and after treatment using paired samples t-tests and median changes were 
compared using nonparametric Wilcoxin signed rank tests for related samples. The 
relationships among the baseline biochemical variables were assessed using the Pearson’s 
correlation tests. Post treatment means for treatment and placebo groups were compared at 
6 months using the unpaired samples t-tests.  The significance threshold was set at α level 
of 0.05.  
 
Linear regression analysis was performed using the “successive steps” method, to 
determine the independent predictors of the difference in homocysteine levels before and 
after the trial, allowing the introduction of a new variable if the P value of the new model 
was less than 0.05, and excluding those yielding a P value higher than 0.10 in each step. 
The independent variables were age, genotype, treatment group (placebo vs vitamin), and 
dietary intake of B6, B12 and folate. All analyses were performed using the Statistical 
Package for Social Sciences (SPSS version 18.0). 
 
Results 
Figure 1 illustrates the patient flow through the trial from January 2009 to January 2010. 
Six hundred and twenty nine migraine patients were assessed for eligibility prior to 
enrolment into trial. 384 migraine patients were excluded from enrolment due to reasons 
such as not meeting inclusion criteria, refusal to participate in placebo controlled trial and 
other reasons. 245 participants were initially enrolled in the trial and were randomly 
assigned to either the placebo group or the vitamin treated group but 3 participants dropped 
out before the commencement of the trial and the remaining 242 participants received 
baseline assessment and commenced the trial. Hundred and nineteen participants were on 
the vitamin treated group and the remaining 123 participants were in the placebo treated 
group. Forty four participants were lost to follow up due to lack of compliance and 162 
participants completed the trial (76 vitamin: 86 placebo). 
 
Baseline analysis 
Table 1 shows the baseline clinical characteristics of the participant group. For the total 
migraine group (n= 206), mean folate concentration was 30.1 nmol/l, which is above the 
average for a general Caucasian population replete for folate (13.7nmol/l)[2]. The mean 
plasma homocysteine concentration for the migraine group was 11.5 µmol/l, which is also 
above the average for a general Caucasian population (8.9 μmol/l)[2]. The mean levels of 
B6 and B12 at baseline fell within the normal range for this patient group. For the total 
group, plasma homocysteine concentration was negatively correlated with plasma folate 
(Pearson’s r = - 0.057, P = 0.438). Vitamin B6 (Pearson’s r = -0.212, P = 0.05), vitamin B12 
(Pearson’s r = - 0.279, P= 0.000). The percentage of participants with high migraine 
disability did not differ significantly between the placebo and the vitamin treated group 
(P=0.18). Similarly the migraine attack frequency (P=0.41) and migraine pain severity (P= 
0.38) did not differ significantly between the placebo and the vitamin treated group. There 
were no statistically significant differences between the vitamin and placebo groups for the 
teat variables at baseline. 
 
Six-month follow-up analysis 
A total of 162 participants completed the trial. 86 of them were on placebo and 76 of them 
were on vitamin supplementation. After 6 months of treatment, the vitamin treated group 
had marked increases in folate, B6, B12 concentration compared with baseline and the 
placebo group (P< 0.001). In the placebo group, the mean folate levels increased by 11.8% 
after 6 months (28.7 – 32.1 nmol/I, P= 0.852). The B12 levels decreased by 6.5% (328.6-
307.1 pmol/I, P= 0.059) and the B6 levels decreased by 7.8% (80.8- 74.5 pmol/I, P= 0.292). 
In the vitamin treated group, the median homocysteine levels reduced by 20% after 6 
months (11.5-9.2 pmol/I, P<0.001) compared with 4.8% reduction observed for the placebo 
group (P=0.121). The effect of treatment on the reduction of homocysteine levels remained 
significant after correction for confounding factors such as age, genotype and dietary 
consumption of vitamin B6, B12 and dietary folate (r
2
=0.042; P = 0.019). The dietary 
consumption of B6, B12 and dietary folate between the vitamin and placebo groups were not 
significantly different at the 6 month follow-up analysis (B6, P=0.721; B12, P= 0.891; 
Dietary folate, P= 0.373).  
 
In the vitamin treated group the frequency of high migraine disability decreased after 6 
months of supplementation from 74% to 56.9% (P=0.022). The reduction in the placebo 
group was not statistically significant (65.3% to 53.2% (P=0.098). Headache frequency did 
not decrease from a median of 2 for both the vitamin (P=0.46) and placebo (P=0.147) 
groups after 6 months. The vitamin treated group reported a decrease in pain severity from 
a median score of 7 to 6 (P= 0.017), whereas the placebo group reported no change (P>0.1).  
 
Treatment response by MTHFRC677T and MTRRA66G genotype 
When the vitamin treated group was stratified by MTHFRC677T genotype, the mean 
homocysteine reduction was 20% for both the CC and the CT group (P<0.001) compared to 
13.3% for the TT carriers (P=0.095) (Figure 2). For further analysis the genotypes (CC and 
CT) that showed the largest decrease in homocysteine levels after vitamin supplementation 
were grouped and their effect on migraine frequency, pain severity and disability were 
analysed. There was no significant reduction in migraine frequency in both CC/CT and the 
TT genotype groups after the trial. The CC/CT genotype group showed a significant 
reduction in migraine pain severity (P= 0.01) with the mean pain scores decreasing from 7 
to 6. This significant reduction was not observed in the TT genotype group (P=0.278) with 
the mean pain scores remaining at 6 before and after the trial. When migraine disability was 
analysed in the CC/CT and TT genotype groups, the percentage of highly disabled 
migraineurs decreased from 77% to 57% after the trial in CC/CT group (P= 0.009) and by 
6.3% in the TT genotype group (P=0.568). 
 
When the vitamin - treated group was stratified by MTRRA66G genotype, the mean 
homocysteine reduction was 27% for the AA carriers (P<0.001), 16% for the AG carriers 
(P= 0.001) compared to 13% for the GG carriers (P=0.03) (Figure 3). For further analysis 
the AA and the AG genotypes of the A66G variant, which showed the largest decrease in 
homocysteine levels after vitamin supplementation were grouped and their effect on 
migraine frequency, pain severity and disability were analysed. Again there was no 
significant change in migraine frequency between the two groups. The A allele carriers of 
the MTRRA66G variant showed a significant reduction in migraine pain severity with the 
pain scores decreasing from 7.1 to 6.2 after the trial (P=0.002). In the GG genotype group 
however, the pain scores increased from 6.3 to 7 (P=0.05). When the percentage of high 
migraine disability was analysed in the two genotype groups, the percentage of highly 
disabled migraineurs decreased from 75.3% to 53.8% in the A allele carriers ( P= 0.006), 
while it only decreased from 68.8% to 66.7% in the GG genotype group (P=0.45). 
 
The C allele carriers of the MTHFRC677T polymorphism and the A allele carriers of the 
MTRRA66G polymorphism were compared with the homozygote mutant allele carriers for 
both genotypes (CC/CT/AA/AG vs TT/GG). There was no significant decrease in migraine 
frequency in the two groups. Migraine head pain severity was however significantly 
decreased after the 6 months of vitamin supplementation in the CC/CT /AA/AG group from 
a pain score of 7 to 6.2 (P=0.002) compared to the TT/GG group, which remained at a 
constant score of 6 (P=0.5) (Figure 4). Similarly migraine disability was significantly 
reduced after the trial in the CC/CT/AA/AG group with the percentage of highly disabled 
migraineurs decreasing from 74.6% to 52.2% (P=0.015) compared to the TT/GG group, 
where the percentage of highly disabled migraineurs decreased from 50% to 33.3% 
(P=0.64) (Figure 5). 
 
Discussion 
Migraine is a chronic and often disabling condition has an enormous impact on both the 
individual sufferer and on society at large [22]. There are several acute care therapies and 
medications currently available that have been successful in either treating migraine 
symptoms or decreasing migraine attacks and several other medications and therapies in 
various stages of development [23]. However current medications and therapies work with 
differing efficacy in migraineurs and are often associated with adverse effects [2]. Thus the 
search for effective, safe and inexpensive migraine therapies to combine with or replace 
current therapies still continues [2].  One of the most significant findings in recent times is 
the involvement of genetics in migraine aetiology, which has added further complexity to 
understanding the pathophysiology underlying migraine. This has made migraine diagnosis 
and treatment options varied and continuously improved.  
 
Mild hyperhomocysteinemia has been reported to increase the risk of artherosclerotic 
vascular disease [24]. MA sufferers have been linked to increased risk of vascular brain 
lesions and ischaemic stroke [25-27]. It is still not clear if homocysteine levels are raised in 
migraineurs; however there is evidence to suggest that the CSD phenomenon observed in 
MA can also occur during a stroke episode [28]. Based on the potential role homocysteine 
may play on the cerebrovascular system and the co morbidity of migraine and stroke, it is 
plausible that homocysteine levels may be involved in the underlying pathophysiology of 
both MA and stroke[29]. The reasons for hyperhomocysteinemia may be varied: mutations 
in the genes for MTHFR, MTRR and CBS or possible nutritional deficiencies in cofactors 
in the homocysteine metabolism [30]. Alternatively, migraineurs may be hyper sensitive to 
folate at “normal” levels. 
 
The current study examined the genotypic effects of the MTHFR and MTRR gene on folate 
and vitamin B treatment response in migraineurs. Vitamin supplementation in the current 
trial was well tolerated by the study group with no reports of adverse reactions. At baseline, 
the homocysteine levels were mildly elevated in the migraine group compared to the 
general Caucasian population with some but not all studies of homocysteine in migraine [2, 
10, 28]. Results of this trial showed the vitamin treatment compared with the placebo 
significantly decreases the homocysteine levels at six months by an average of 2.2 µmol/l, 
an effect size in Australian Caucasian female MA sufferers. This decrease in homocysteine 
levels remained significant after correcting for dietary consumption of folate, B6 and B12. 
 
The 2.2 µmol/l reduction in the homocysteine levels at 6 months in the current trial 
approximates the 2.0 µmol/l reduction observed in the “Vitamin Intervention for Stroke 
Prevention (VISP) trial, which randomised 3680 stroke survivors of primarily white origin 
from North America to receive high-dose (folic acid 2.5mg; B6 25mg: B12 0.4 mg) or low 
dose folic acid 20 µg; B6 200ug; B12 0.6 µg)[31]. However the 2.2 µmol/l reduction in 
homocysteine levels observed in the current trial is lower compared to the 4.0 µmol/l 
reduction observed in a study by Lea et al in 2009 that investigated the effect of vitamin 
supplementation and MTHFR (C677T) genotype on homocysteine- lowering and migraine 
disability in 52 Australian Caucasians [2]. The difference in decrease of homocysteine 
levels in the vitamin groups of both trials was not statistically significant ( Lea et al 2009 
trial- 39% vs 20% - current trial : P= 0.475). 
 
The smaller than expected treatment effect of the prescribed dosage of vitamins seen in the 
current trial in comparison to the earlier trial by Lea et al in 2009 , is most likely 
attributable to the implementation on September 2009, of fortification of wheat flour for 
bread making with folic acid in Australia, which coincided with the conduct of the trial. 
The mean folate levels of the participants in the vitamin group at baseline in the current 
trial (31.4nmol/l) was significantly higher (P<0.001) than those in the Lea et at 2009 trial 
(11.2nmol/l). While there was no statistically significant difference between the B12 and B6 
levels at baseline between the two trials (P<0.4). It has been evidenced in clinical trials in 
cardiovascular disease, that mandatory folic acid fortification has influenced the 
homocysteine-lowering effects of folic acid [31]. Moreover it has been observed that trials 
conducted in countries with mandatory folate fortification show narrower differences in 
homocysteine reduction for study groups than trials conducted in countries without folate 
fortification [32, 33]. 
 
Participants may have failed to take a “MigraVitTM ” pill everyday of the 6 months trial 
period and although participants were asked to record details of their daily diet and days 
where they had missed taking the prescribed “MigraVitTM” pill, this may not have been 
accurately reported or detailed in the migraine diary they were provided with. These may 
also be reasons that could have contributed to the lower levels of homocysteine reduction 
observed in the current trial in comparison to the previous trial by Lea et al 2009[2]. 
 
There was significant reduction in migraine pain severity and disability according to the 
MIDAS instrument scores in the vitamin treated group. This decrease was greater overall 
compared with the placebo effect, which was not statistically significant (Figure 3).  
However the frequency of migraine headache did not decrease from a median of 2 in the 
vitamin treated group, which is inconsistent to that observed in the pilot study by Lea et al 
that reported a decrease from a median of 4 to 1 in migraine headache frequency in the 
vitamin treated group[2]. The absence of significant reduction in migraine headache 
frequency observed in this trial may be attributable to the fact that the trial population only 
had a median headache frequency of 2 at baseline. A population of median headache 
frequency of 4 and more at baseline may have yielded a significant reduction in headache 
frequency after the prescribed vitamin treatment.  
 
When the effects of the MTHFRC677T variant on treatment effect in migraineurs was 
assessed in the current study, a significant reduction in homocysteine levels in the C allele 
carriers compared to the mutant homozygote TT genotype carriers was observed. Further 
analysis found the C allele carriers to respond better to vitamin supplementation in lowering 
migraine pain severity and high migraine disability compared to the TT genotype carriers.  
These results are supported by similar findings reported in the pilot study by Lea et al [2] 
and adds to the idea that individuals with TT genotypes, having a 50% reduction in their 
enzymatic rate, are genetically slower in homocysteine metabolism and thus would require 
an increased dosage of vitamins compared with the C allele carriers to experience the same 
reduction in homocysteine levels and consequent migraine symptoms. Similarly when the 
analysis was stratified by the MTRRA66G variant, the A allele carriers showed the largest 
reduction in homocysteine levels and migraine pain severity and high migraine disability 
under vitamin supplementation compared to the mutant homozygote GG genotype carriers.. 
The combined effects of the C and A allele carriers of the C677T and A66G variants 
respectively, showed significant reduction in migraine pain severity and migraine disability. 
However the combined effect of the two variants was not significantly different from the 
independent effect of the two variants on migraine pain severity and disability. This 
suggests that both the MTHFRC677T and MTRRA66G appear to be acting independently 
from one another in affecting vitamin treatment response in migraineurs. 
 
The MTHFR product, 5-methyl-THF, donates a methyl group for the remethylation of 
homocysteine to methionine, which is catalysed by MTR in a vitamin B12 dependent 
reaction. MTR may become inactive due to oxidation of its vitamin B12 cofactor and 
restoration of MTR activity is dependent on reductive remethylation of vitamin B12 by 
MTRR [34]. The functional effects of the MTRR A66G variant have not been fully 
understood, however in vivo experiments suggest that the A66G variant MTRR enzyme 
restores MTR activity less efficiently than wild-type [35], and has also been shown to 
increase plasma homocysteine levels in humans [36, 37]. When the MTHFR 677TT 
genotype occurred with either the homozygous or heterozygous genotype for the MTRR 
A66G variant, it may exacerbate the effect of the MTHFR variant alone [18].  
 
Genes involved in the homocysteine pathway play a crucial role in the amount of 
homocysteine in the extracellular media such as plasma [38]. The allele groups of MTHFR 
and MTRR that showed the largest reduction in homocysteine levels showed the most 
significant reduction in migraine pain severity and disability under vitamin treatment. There 
is an undeniable relationship between homocysteine levels and migraine disability. The 
homozygote mutant allele carriers of the MTHFR and MTRR variant may need a higher 
dose of vitamin supplementation to experience the same effect as the wild type allele 
carriers of the variants, in migraine pain severity and disability reduction. Further clinical 
trials of higher doses of vitamin supplementation are required to make an evidence based 
argument of this idea. The effects of hyperhomocysteinemia may be a partial determinant 
for the neuro and/or vascular pathologies underlying MA and stroke [2]. Other genes and 
functional variants associated with the homocysteine metabolism cascade other than the 
MTHFR and MTRR have to be investigated in relation to vitamin treatment response in 
migraineurs.  
 
Conclusion 
The current study has added further evidence that homocysteine reduction through vitamin 
supplementation may reduce migraine disability in a subgroup of patients and that the 
MTHFR and MTRR variants both contribute an independent effect on migraine treatment 
response.  
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Tables 
Table 1: 
Variable Total Vitamin Placebo P-value* 
No.patients 206 103 103  
Age in years, mean(SD)
b
 44(13) 42(13) 45(13) 0.65 
Female  206    
Folate, mean (SD)
b
 30.1(12.5) 31.4(12.8) 28.7(12.2) 0.56 
Vitamin B12, mean (SD)
b
 322.7(148.5) 315.7(114.9) 328.6(175.7) 0.15 
Vitamin B6, mean (SD)
b
 78.8(12.6) 77(11.9) 80.8(13.5) 0.82 
Homocysteine, mean (SD)
b
 11.5(3.4) 11.6(3.6) 11.5(3.3) 0.7 
B12ug consumption, mean (SD)
b
 1.01(0.5) 1.1(0.5) 0.9(0.5) 0.9 
B6mg consumption, mean (SD)
b
 1.7(0.6) 1.7(0.7) 1.7(0.6) 0.13 
Folate ug consumption, median (range)
a
 428.7(225.6) 433(239) 424(212) 0.74 
High migraine disability (%)
a
 69.7 74% 65.30% 0.18 
Attack frequency median (range)
a
 2 (1-6) 2(1-6) 2(1-4) 0.41 
Head pain score median (range)
a
 7(3.5-10) 7(1-10) 7(3.5-10) 0.38 
MTHFR C677T (TT) genotype % 15.3 18.3 12.4 0.46 
MTRR A66G (GG) genotype % 25.4 19.6 30.9 0.15 
MTHFR C677T, methlenetetrahydrofolate gene    
MTRR A66G Methionine synthase reductase gene    
a 
Based on a 3-month history.     
b
 Average daily consumption.      
* All P values are two-tailed.     
     
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures  
Figure 1: Patient flow chart for the trial 
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Figure 2 
 
 
Change in homocysteine levels over the treatment period in vitamin treated group stratified 
by the MTHFRC677T variant. Values are represented as mean + SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Change in homocysteine levels over trial period in vitamin group 
7 
8 
9 
10 
11 
12 
13 
14 
CC CT TT 
MTHFRC677T genotype 
M
ea
n
 H
cy
 (
µ
m
o
l/
l)
 
Baseline 
6 months 
Figure 3 
 
Change in homocysteine levels over the treatment period in vitamin treated group stratified 
by the MTRRA66G variant. Values are represented as mean + SEM. 
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Change in average pain score over treatment period for vitamin treated group with the 
MTHFR677, CC and CT genotypes combined with the MTRR66 AA and AG genotypes 
group and the MTHFR667 TT genotype combined with the MTRR 66 GG genotype group. 
Quartiles are not shown but reductions are statistically significant (P<0.05). 
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Figure 5 
 
 
 
Change in frequency of high-level of migraine disability as measured by the Migraine 
Disability Score (MIDAS) instrument (MIDAS> 11) over the treatment period in the 
MTHFR677, CC and CT genotypes combined with the MTRR66 AA and AG genotypes 
group and the MTHFR667 TT genotype combined with the MTRR 66 GG genotype group. 
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